Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 1996

View Archived Issues

Lilly's tachykinin antagonists for chronic pain

ADCON-L efficacy reported

BMS discloses novel cephalosporins

MBI-10 antibiotics effective against resistant staphylococci

Pfizer, Microcide to codevelop antibacterial drugs

BILD-1351 for HSV infection

Lidakol formulations receive patent protection

Nabi foresees phase I/II trials on CMV NeutraGAM

Virend entering phase III

New protease inhibitors from BMS

DuPont Merck research into protease inhibitors

New data, new approvals for DaunoXome

ImmuCell arranges for clinical evaluation of CryptoGAM

PEG-rhSOD advancing in preclinical phase

Spartaject busulfan to enter phase I

New daunorubicin derivative from P&U

Yakult Honsha claims camptothecin derivatives

Sparta to develop new camptothecin formulations

Boehringer Mannheim synthesizes antitumor anthrapyrazoles

Sparta develops new formulations of taxanes

Roussel Morishita reports new aromatase inhibitor

PPI-149 selected for development

MAbs for treatment of melanoma

BMS reports mutant BR96 antibodies

Antineoplastic fusion proteins from Bristol-Myers Squibb

Protein kinase C modulators in the pipeline at Procyon

SU-101 designated orphan drug

Merck & Co. reports farnesyl transferase inhibitors

PD-145709: New tyrosine kinase inhibitor from Warner-Lambert

Regeneron investigates Tie-2 ligand

New angiogenesis inhibitors from ADIR

Kyowa Hakko discloses UCF76-B

New telomerase inhibitor from Geron

New antitumor proteins from Alfacell

Oncogene Science, Pfizer extend research agreement

Lu-Tex clinical update

Scotia accelerates development of temoporfin

Seed implant treatment effective in prostate cancer

Vitronectin antagonist from Merck & Co. inhibits bone resorption

Cortecs licenses salmon calcitonin to Teva

Pierre Fabre reports hypocholesterolemic organosilanes

ACAT inhibitors claimed by DuPont Merck

Warner-Lambert discloses ACAT inhibitors

BMS claims beta3 agonists in patent literature

Progenitor patent on leptin receptor published

Agennix collaboration with Gist-Brocades for lactoferrin

RSR13 enhances oxygen delivery to tissues

Pharmalytics develops anticocaine drugs

RIGScan CR49 clinical data presented

Axcan to distribute Helisal in Canada

Molecular Biosystems presents preliminary FS069 study results

Molecular Biosystems, Shionogi agreement on the rocks

Ostex's NTx assay highly sensitive, specific in detecting bone turnover

Alzheimer's diagnostics introduced in U.S.

Coronary artery diagnostic to enter clinical studies

Pherin develops vomeropherins for anxiety

Meiji claims improved antipsychotic agents

New antipsychotic drugs from HMR

New antipsychotic drug in phase I at P&U

L-745870: D4 antagonist for schizophrenia

New anthranilide in phase I at Glaxo Wellcome

5-HT1A/5-HT2C receptor ligands from Roche

Synthelabo reports antidepressants

Chiron, Japan Tobacco alliance for combinatorial chemistry

FDA approves Laser system for myopia

Neugenesis profile

Aristogen to offer genetic diagnostic services in Germany

Stanford investigators identify epilepsy gene

Anticonvulsants claimed by Bristol-Myers Squibb

SYM-2206 for seizure prevention

Roche Bioscience claims antiemetic drugs

Schering-Plough claims felbamate metabolite

PPI-368 selected for development

Eisai claims cerebral antiischemic

Novel ETA/ETB antagonist reduces brain injury

TR-810 delivers SOD to the nervous system

GV-150526A in development for stroke

SIBIA , Ciba-Geigy collaborate to develop CNS drugs

Zeneca selects NMDA antagonist for preclinical study

Genentech files for new indication for alteplase

New antiallergics from Japan Energy

More new antiallergics from Japan Energy

Suntory reports antiallergy agents

New PAF antagonist discovered at Abbott

rPAF-AH moves to phase I

Vitronectin receptor antagonist revealed by SmithKline Beecham

Genentech claims vitronectin antagonists

New potassium channel openers from Nippon Kayaku

Cypros synthesizes adenosine deaminase inhibitors

Baxter to distribute coronary bypass graft

PB-005 slated to enter phase II

Novel vasoprotectants in AtheroGenics' pipeline

BXT-51072 in line for clinical evaluation at Oxis

Another antioxidant from Oxis: TX-153

New antiarrhythmics from Nisshin Flour Milling

Na+/H+-exchange inhibitors reported by Hoechst

E. Merck claims Na+/H+-exchange inhibitors

New agent for sudden cardiac death in phase I at Nortran

New endothelin antagonists from RPR reported at 211th ACS

Platelet antiaggregatory prostaglandins reported by Taisho

Scripps Research Institute reports fibrinogen antagonists

SB-214857 in preclinical studies

FDA approves lasers for treating BPH

Provir to enter phase II soon

Jones Medical will market thiamazole in U.S.

Lilly claims glucagon-like peptide fragments

HGH delivery agents reported by Emisphere Technologies

Sae Han to distribute erectile dysfunction treatment in Korea

Vivelle U.S. launch

Generic fluoxetine available in Canada

Teijin reveals new agent for restenosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...